Short answer
Beta Bionics, Inc. (BBNX) filed an 8-K current report with the SEC on September 17, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). $150.0M gross public offering, comprising 7,652,175 common shares and pre-funded warrants for 1,043,484 shares.
Beta Bionics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $150.0M gross public offering, comprising 7,652,175 common shares and pre-funded warrants for 1,043,484 shares
- $17.25 per share offering price, with $0.0001 exercise price on pre-funded warrants
- Potential dilution from underwriters’ 30-day option for 1,304,348 additional shares
- Proceeds earmarked for Mint commercialization, manufacturing expansion, development, strategic opportunities and working capital
- Closing expected September 17, 2026, subject to customary conditions
Item EX-99.1 · Exhibit EX-99.2
- Proposed $125.0 million underwritten common-stock offering, subject to market conditions and completion risk
- Potential $18.75 million additional shares through underwriters’ 30-day option
- Proceeds targeted for Mint commercialization, manufacturing expansion, research, development, product enhancements, and working capital
- Primary financing creates shareholder dilution while funding growth initiatives
- J.P. Morgan, Piper Sandler, Wells Fargo Securities, and Leerink Partners serving as joint book-running managers
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Beta Bionics, Inc. 8-K filings
Get the next BBNX 8-K as it lands
Follow BBNX for push alerts, or ask the research agent what this filing means.